PACIRA PHARMACEUTICALS INC's ticker is PCRX and the CUSIP is 695127100. A total of 261 filers reported holding PACIRA PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 0.66 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,025 | -19.8% | 33,404 | +4.7% | 0.00% | 0.0% |
| Q2 2023 | $1,278 | -8.2% | 31,911 | -6.4% | 0.00% | 0.0% |
| Q1 2023 | $1,392 | +31.4% | 34,089 | +24.3% | 0.00% | – |
| Q4 2022 | $1,059 | -99.9% | 27,418 | +57.7% | 0.00% | -100.0% |
| Q3 2022 | $924,000 | -30.8% | 17,385 | -24.1% | 0.00% | 0.0% |
| Q2 2022 | $1,335,000 | -58.4% | 22,905 | -45.5% | 0.00% | -66.7% |
| Q1 2022 | $3,206,000 | -62.9% | 41,993 | -70.7% | 0.00% | +50.0% |
| Q4 2021 | $8,636,000 | +155.6% | 143,504 | +137.8% | 0.00% | 0.0% |
| Q3 2021 | $3,379,000 | +85.9% | 60,337 | +101.4% | 0.00% | +100.0% |
| Q2 2021 | $1,818,000 | -53.5% | 29,964 | -46.3% | 0.00% | -50.0% |
| Q1 2021 | $3,909,000 | +19.2% | 55,761 | +1.8% | 0.00% | 0.0% |
| Q4 2020 | $3,278,000 | +5.1% | 54,768 | +5.5% | 0.00% | 0.0% |
| Q3 2020 | $3,120,000 | +51.8% | 51,906 | +32.5% | 0.00% | 0.0% |
| Q2 2020 | $2,056,000 | +54.7% | 39,185 | -1.1% | 0.00% | +100.0% |
| Q1 2020 | $1,329,000 | -55.9% | 39,626 | -40.5% | 0.00% | -50.0% |
| Q4 2019 | $3,017,000 | +58.5% | 66,623 | +33.2% | 0.00% | +100.0% |
| Q3 2019 | $1,904,000 | +5.3% | 50,026 | +20.3% | 0.00% | 0.0% |
| Q2 2019 | $1,809,000 | -20.9% | 41,593 | -30.8% | 0.00% | -50.0% |
| Q1 2019 | $2,288,000 | +662.7% | 60,145 | +761.8% | 0.00% | – |
| Q4 2018 | $300,000 | -72.3% | 6,979 | -68.3% | 0.00% | -100.0% |
| Q3 2018 | $1,084,000 | +301.5% | 22,038 | +162.0% | 0.00% | – |
| Q2 2018 | $270,000 | -98.1% | 8,411 | -98.2% | 0.00% | -100.0% |
| Q1 2018 | $14,549,000 | +426.4% | 467,058 | +671.6% | 0.01% | +450.0% |
| Q4 2017 | $2,764,000 | -57.1% | 60,530 | -64.8% | 0.00% | -71.4% |
| Q3 2017 | $6,449,000 | +2014.4% | 171,725 | +2574.4% | 0.01% | – |
| Q2 2017 | $305,000 | -98.5% | 6,421 | -98.5% | 0.00% | -100.0% |
| Q1 2017 | $19,823,000 | +72.9% | 434,721 | +22.4% | 0.02% | +61.5% |
| Q4 2016 | $11,465,000 | +820.1% | 355,020 | +874.3% | 0.01% | +550.0% |
| Q3 2016 | $1,246,000 | +80.1% | 36,439 | +77.6% | 0.00% | +100.0% |
| Q2 2016 | $692,000 | -90.2% | 20,523 | -84.9% | 0.00% | -90.9% |
| Q1 2016 | $7,048,000 | -5.9% | 135,547 | +37.5% | 0.01% | +22.2% |
| Q4 2015 | $7,491,000 | +1431.9% | 98,591 | +726.1% | 0.01% | +800.0% |
| Q3 2015 | $489,000 | -88.1% | 11,934 | -79.7% | 0.00% | -75.0% |
| Q2 2015 | $4,119,000 | +717.3% | 58,841 | +927.1% | 0.00% | – |
| Q1 2015 | $504,000 | -81.4% | 5,729 | -81.4% | 0.00% | -100.0% |
| Q4 2014 | $2,705,000 | -29.4% | 30,721 | -23.0% | 0.00% | -33.3% |
| Q3 2014 | $3,831,000 | -47.6% | 39,900 | -50.4% | 0.00% | -57.1% |
| Q2 2014 | $7,316,000 | +119.2% | 80,395 | +66.2% | 0.01% | +75.0% |
| Q1 2014 | $3,338,000 | +5035.4% | 48,383 | +4189.3% | 0.00% | – |
| Q4 2013 | $65,000 | -38.1% | 1,128 | -48.3% | 0.00% | – |
| Q3 2013 | $105,000 | -71.8% | 2,180 | -83.0% | 0.00% | – |
| Q2 2013 | $373,000 | – | 12,846 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GAGNON SECURITIES LLC | 563,415 | $21,753,453 | 4.80% |
| Gagnon Advisors, LLC | 180,331 | $6,962,579 | 4.70% |
| Spyglass Capital Management LLC | 868,686 | $33,539,966 | 2.69% |
| Tamarack Advisers, LP | 100,000 | $3,861,000 | 1.99% |
| ARMISTICE CAPITAL, LLC | 1,892,000 | $73,050,120 | 1.27% |
| NEUMEIER POMA INVESTMENT COUNSEL LLC | 276,590 | $10,679,140 | 0.99% |
| RICE HALL JAMES & ASSOCIATES, LLC | 437,285 | $16,883,574 | 0.97% |
| Rock Springs Capital Management LP | 1,032,600 | $39,868,686 | 0.96% |
| OUTFITTER FINANCIAL LLC | 25,860 | $998,455 | 0.91% |
| Stephens Investment Management Group LLC | 1,168,469 | $45,535,237 | 0.82% |